England’s National Institute for Health and Care Excellence (NICE), and Canada’s Drug Agency (CDA-AMC) have formed the Health Economics Methods Advisory (HEMA) initiative. The goal of HEMA is to ...

Massachusetts, USA-based cell therapy specialist Abcuro today announced the closing of a $200 million Series C financing.

An Expert View from Nick Petschek, EMEA managing director at global change management firm Kotter International.

US pharma major AbbVie has announced a deal with Xilio Therapeutics, more than doubling the latter’s share price.

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech’s litifilimab.

Biogen reported fourth-quarter 2024 earnings that surpassed analysts' expectations, driven by strong sales of new product ...

At least 90% of drugs from the list of vital medicines in Russia will be of domestic origin already by the end of 2025, ...

The US Food and Drug Administration approved Gomekli (mirdametinib), from SpringWorks Therapeutics, a kinase inhibitor, for adult and pediatric patients two years of age and older with ...

American biotech Third Harmonic Bio and Inventiva have announced plans to reduce their respective workforces by 50% as part of cost-cutting measures. Both companies are shifting their focus to a ...

US biotech major Gilead Sciences was trading nearly 5% higher in Wednesday’s pre-market trading after presenting its fourth ...

US biotech Voyager Therapeutics saw its shares close down 21% at $4.20 on Tuesday, after it revealed its decision to assess ...

Belgium’s largest drugmaker UCB today released long-term data from the BE HEARD^ trials for Bimzelx (bimekizumab) in moderate ...